BIOTECHNOLOGY VALUE FUND II LP

Director at CTI BIOPHARMA CORP · on record since Jun 28, 2023
Director at Olema Pharmaceuticals, Inc. · on record since Jun 21, 2023
See explanation of responses at Structure Therapeutics Inc. · on record since Feb 13, 2023
Direct Beneficial Owner at AMAG PHARMACEUTICALS, INC. · on record since Jan 13, 2006
10% owner at VIACELL INC · on record since Oct 17, 2007
10% owner at AEOLUS PHARMACEUTICALS, INC. · on record since Feb 13, 2006
10% owner at Repare Therapeutics Inc. · on record since Nov 17, 2023
See Explanation of Responses at enGene Therapeutics Inc. · on record since Nov 13, 2023
See Explanation of Responses at POINT Biopharma Global Inc. · on record since Nov 6, 2023
Director at Rain Oncology Inc. · on record since Jan 29, 2024
See Remarks; Former 10% Owner at Rain Oncology Inc. · on record since Apr 27, 2021
See Explanation of Responses at Allakos Inc. · on record since Jan 26, 2024
See Explanation of Responses at Xenon Pharmaceuticals Inc. · on record since Sep 12, 2016
See Explanation of Responses at KENT FINANCIAL SERVICES INC · on record since Dec 28, 2011
Direct Beneficial Owner at ADOLOR CORP · on record since Oct 31, 2008
Direct Beneficial Owner at VIACELL INC · on record since Nov 26, 2007
Direct Beneficial Owner at NPS PHARMACEUTICALS INC · on record since Mar 20, 2008
Direct Beneficial Owner at · on record since Jun 26, 2008
Direct Beneficial Owner at · on record since Jun 20, 2008
Direct Beneficial Owner at · on record since May 13, 2008
Director at · on record since Feb 27, 2026
See Explanation of Responses at · on record since Feb 27, 2026
Direct Beneficial Owner at · on record since Nov 26, 2008
Direct Beneficial Owner at · on record since Nov 20, 2008
Direct Beneficial Owner at · on record since Nov 7, 2008
Direct Beneficial Owner at · on record since Apr 29, 2009
Direct Beneficial Owner at · on record since Jun 5, 2009
10% owner at · on record since Jul 11, 2003
10% owner at · on record since Jul 13, 2009
10% owner at · on record since Sep 10, 2009
Direct Beneficial Owner at · on record since Jul 8, 2009
Direct Beneficial Owner at · on record since Jul 17, 2003
10% owner at · on record since Dec 24, 2009
Direct Beneficial Owner at · on record since Jul 22, 2003
See Footnote 1 at · on record since Jul 22, 2003
Direct Beneficial Owner at · on record since Jan 29, 2010
Insider at · on record since Nov 20, 2013
10% owner at · on record since Mar 23, 2011
Director at · on record since Apr 2, 2026
10% owner at · on record since Apr 2, 2026
See Footnote (1) at · on record since Sep 5, 2003
See Explanation of Responses at · on record since Jun 29, 2011
Direct Beneficial Owner at · on record since Apr 22, 2011
See Explanation of Responses at · on record since Oct 14, 2011
See Explanation of Responses at · on record since Sep 9, 2011
See Explanation of Responses at · on record since Oct 7, 2011
Direct Beneficial Owner at · on record since Oct 21, 2003
Direct Beneficial Owner at · on record since Oct 29, 2003
Direct Beneficial Owner at · on record since Nov 7, 2003
10% owner at · on record since Dec 30, 2016
10% owner at · on record since May 18, 2026
See Footnotes (1)(2) at · on record since Jan 20, 2004
See Explanation of Responses at · on record since Mar 26, 2014
See Explanation of Responses at · on record since Mar 25, 2014
See Footnotes (1) (2) at · on record since Feb 18, 2004
See Explanation of Responses at · on record since Jul 16, 2014
See Explanation of Responses at · on record since Jun 11, 2015
See Explanation of Responses at · on record since Aug 21, 2015
See Explanation of Responses at · on record since Dec 14, 2015
10% owner at · on record since Jun 27, 2016
See Explanation of Responses at · on record since Dec 2, 2016
See Explanation of Responses at · on record since Feb 21, 2017
See Explanation of Responses at · on record since Jun 22, 2017
See Explanation of Responses at · on record since May 11, 2017
See footnote (1) at · on record since Feb 1, 2005
10% owner at · on record since Feb 1, 2005
See Explanation of Responses at · on record since Sep 29, 2017
See Explanation of Responses at · on record since Nov 27, 2017
See Explanation of Responses at · on record since Dec 8, 2017
See Explanation of Responses at · on record since Jun 22, 2026
See Explanation of Responses at · on record since Nov 26, 2018
See Explanation of Responses at · on record since Nov 9, 2018
See Explanation of Responses at · on record since Jul 1, 2019
See Explanation of Responses at · on record since Oct 31, 2019
See Explanation of Responses at · on record since Dec 12, 2019
See Explanation of Responses at · on record since Jan 21, 2020
See Explanation of Responses at · on record since Jun 22, 2020
See Explanation of Responses at · on record since Aug 20, 2020
See Explanation of Responses at · on record since Dec 28, 2020
See Explanation of Responses at · on record since Dec 28, 2020
See Explanation of Responses at · on record since Nov 20, 2020
See Explanation of Responses at · on record since Nov 8, 2021
See Explanation of Responses at · on record since Jan 10, 2022
See Explanation of Responses at · on record since Feb 7, 2022
See Explanation of Responses at · on record since Jun 27, 2022
Director at · on record since May 20, 2022
See Explanation of Responses at · on record since Jul 21, 2022
See Explanation of Responses at · on record since Dec 22, 2022
Director at · on record since Jan 13, 2023
See Remarks and Footnotes at · on record since Aug 25, 2020
10% owner at · on record since Oct 5, 2026

Insider trading activity of BIOTECHNOLOGY VALUE FUND II LP

Transactions on record: 315; since Jan 13, 2006

Open-market buys: 201; $133.2M

Open-market sells: 66; $58.1M

Companies traded: 30; last filing May 19, 2025

Figures computed from official regulatory filings — .

Companies where BIOTECHNOLOGY VALUE FUND II LP has traded

3 tx · May 19, 2025
3 tx · $17.4M · Oct 31, 2024
9 tx · $30M · Aug 22, 2024
1 tx · Jun 10, 2024
8 tx · Jan 29, 2024
12 tx · $17.7M · Jan 9, 2023
3 tx · $879.8K · Dec 22, 2022
6 tx · $16M · Jun 15, 2022
24 tx · $21.6M · Nov 20, 2020
6 tx · $21.7M · Jun 3, 2020
3 tx · $3.9M · Nov 7, 2019
3 tx · $5.3M · Sep 9, 2019
13 tx · $1.4M · Dec 17, 2018
12 tx · $9.5M · Apr 20, 2018

Track record of BIOTECHNOLOGY VALUE FUND II LP

Statistical track record

Free account

Open-market buys: 206

Last buy: Oct 29, 2024

Win rates, median returns and the proven-insider analysis come with a free account.

Transaction history of BIOTECHNOLOGY VALUE FUND II LP

Co-insiders of BIOTECHNOLOGY VALUE FUND II LP

This page republishes public regulatory disclosures.

Company	Filed	Type	Qty	Price	Value · USD	Signals	Src
Allakos Inc.Listing unverified	May 19, 2025	Other	-6,777,935	—	n/a (No price was disclosed in the filing)		SEC
Allakos Inc.Listing unverified	May 19, 2025	Other	-8,679,726	—	n/a (No price was disclosed in the filing)		SEC
Allakos Inc.Listing unverified	May 19, 2025	Other	-855,211	—	n/a (No price was disclosed in the filing)		SEC
Eledon Pharmaceuticals, Inc.Listing on record	Oct 31, 2024	BuyD (derivative)	2,100,244	3.65 USD	$7.7M	Unusual size	SEC
Eledon Pharmaceuticals, Inc.Listing on record	Oct 31, 2024	BuyD (derivative)	440,489	3.65 USD	$1.6M		SEC
Eledon Pharmaceuticals, Inc.Listing on record	Oct 31, 2024	BuyD (derivative)	2,213,816	3.65 USD	$8.1M	Unusual size	SEC
Kymera Therapeutics, Inc.Listing on record	Aug 22, 2024	BuyD (derivative)	201,546	40.75 USD	$8.2M	Unusual sizeFirst in 12mo	SEC
Kymera Therapeutics, Inc.Listing on record	Aug 22, 2024	BuyD (derivative)	156,742	40.75 USD	$6.4M	First in 12mo	SEC
MoonLake ImmunotherapeuticsListing on record	Jun 10, 2024	AwardD (derivative)	7,688	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	Other	-2,076,085	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	Other	-1,367,838	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	Other	-185,388	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	Other	-1,734,960	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	OtherD (derivative)	-20,000	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	Other	-341,547	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	Other	-2,870,985	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	OtherD (derivative)	-35,000	—	n/a (No price was disclosed in the filing)		SEC
Kymera Therapeutics, Inc.Listing on record	Jan 13, 2023	Buy	15,912	31.24 USD	$497.1K	conv 4	SEC
Kymera Therapeutics, Inc.Listing on record	Jan 13, 2023	Buy	11,149	29.89 USD	$333.2K	conv 4	SEC
Kymera Therapeutics, Inc.Listing on record	Jan 13, 2023	Buy	2,985	31.24 USD	$93.3K	conv 4	SEC
Kymera Therapeutics, Inc.Listing on record	Jan 13, 2023	Buy	10,961	29.89 USD	$327.6K	conv 4	SEC
XOMA Royalty CorpSecurity delisted	Jan 9, 2023	Buy	3,330	18.39 USD	$61.2K	conv 11	SEC
XOMA Royalty CorpSecurity delisted	Jan 9, 2023	Buy	15,670	18.39 USD	$288.2K	conv 11	SEC
XOMA Royalty CorpSecurity delisted	Jan 9, 2023	Buy	1,573	21.98 USD	$34.6K	conv 10	SEC
XOMA Royalty CorpSecurity delisted	Jan 9, 2023	Buy	1,676	21.98 USD	$36.8K	conv 10	SEC

Company	Filed	Type	Qty	Price	Value · USD	Signals	Src
Allakos Inc.Listing unverified	May 19, 2025	Other	-6,777,935	—	n/a (No price was disclosed in the filing)		SEC
Allakos Inc.Listing unverified	May 19, 2025	Other	-8,679,726	—	n/a (No price was disclosed in the filing)		SEC
Allakos Inc.Listing unverified	May 19, 2025	Other	-855,211	—	n/a (No price was disclosed in the filing)		SEC
Eledon Pharmaceuticals, Inc.Listing on record	Oct 31, 2024	BuyD (derivative)	2,100,244	3.65 USD	$7.7M	Unusual size	SEC
Eledon Pharmaceuticals, Inc.Listing on record	Oct 31, 2024	BuyD (derivative)	440,489	3.65 USD	$1.6M		SEC
Eledon Pharmaceuticals, Inc.Listing on record	Oct 31, 2024	BuyD (derivative)	2,213,816	3.65 USD	$8.1M	Unusual size	SEC
Kymera Therapeutics, Inc.Listing on record	Aug 22, 2024	BuyD (derivative)	201,546	40.75 USD	$8.2M	Unusual sizeFirst in 12mo	SEC
Kymera Therapeutics, Inc.Listing on record	Aug 22, 2024	BuyD (derivative)	156,742	40.75 USD	$6.4M	First in 12mo	SEC
MoonLake ImmunotherapeuticsListing on record	Jun 10, 2024	AwardD (derivative)	7,688	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	Other	-2,076,085	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	Other	-1,367,838	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	Other	-185,388	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	Other	-1,734,960	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	OtherD (derivative)	-20,000	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	Other	-341,547	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	Other	-2,870,985	—	n/a (No price was disclosed in the filing)		SEC
Rain Oncology Inc.Listing unverified	Jan 29, 2024	OtherD (derivative)	-35,000	—	n/a (No price was disclosed in the filing)		SEC
Kymera Therapeutics, Inc.Listing on record	Jan 13, 2023	Buy	15,912	31.24 USD	$497.1K	conv 4	SEC
Kymera Therapeutics, Inc.Listing on record	Jan 13, 2023	Buy	11,149	29.89 USD	$333.2K	conv 4	SEC
Kymera Therapeutics, Inc.Listing on record	Jan 13, 2023	Buy	2,985	31.24 USD	$93.3K	conv 4	SEC
Kymera Therapeutics, Inc.Listing on record	Jan 13, 2023	Buy	10,961	29.89 USD	$327.6K	conv 4	SEC
XOMA Royalty CorpSecurity delisted	Jan 9, 2023	Buy	3,330	18.39 USD	$61.2K	conv 11	SEC
XOMA Royalty CorpSecurity delisted	Jan 9, 2023	Buy	15,670	18.39 USD	$288.2K	conv 11	SEC
XOMA Royalty CorpSecurity delisted	Jan 9, 2023	Buy	1,573	21.98 USD	$34.6K	conv 10	SEC
XOMA Royalty CorpSecurity delisted	Jan 9, 2023	Buy	1,676	21.98 USD	$36.8K	conv 10	SEC